SCHEMBL5362266

SCHEMBL5362266

Cc1ccsc1C=C1C(=O)Nc2ccc(NC(=O)CCC3CCCNC3)cc21

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 4/20 0.46
▸ HDAC1 Q13547 4/20 0.46
▸ HDAC2 Q92769 4/20 0.46
▸ HDAC4 P56524 3/20 0.46
▸ HDAC7 Q8WUI4 3/20 0.46
▸ HDAC10 Q969S8 3/20 0.46
▸ HDAC11 Q96DB2 3/20 0.46
▸ HDAC8 Q9BY41 3/20 0.46
▸ HDAC6 Q9UBN7 3/20 0.46
▸ HDAC9 Q9UKV0 3/20 0.46
▸ HDAC5 Q9UQL6 3/20 0.46
▸ TLK2 Q86UE8 2/20 0.45
▸ PAK1 Q13153 12/20 0.45
▸ ROCK2 O75116 1/20 0.43
▸ PDGFRB P09619 2/20 0.42
▸ FLT1 P17948 2/20 0.42
▸ KDR P35968 2/20 0.42
▸ PDGFRA P16234 1/20 0.41
▸ NOX4 Q9NPH5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369667 0.85 HDAC3 (0.65) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL5357950 0.85 PAK1 (0.46) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL5373331 0.81 TLK2 (0.67) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL5366320 0.78 FLT3 (0.54) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL8429175 0.78 PAK1 (0.68) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL8429168 0.78 PAK1 (0.68) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL5361229 0.77 AKT2 (0.59) —
SCHEMBL8411247 0.76 MAPK1 (0.70) TLK2PAK1ROCK2PDGFRBKDR
SCHEMBL8411239 0.76 MAPK1 (0.70) TLK2PAK1ROCK2PDGFRBKDR
SCHEMBL5366906 0.74 AKT2 (0.48) HDAC3HDAC1HDAC2HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 — — US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 — — US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK HDAC3 4513/4885HDAC1 4100/4885HDAC2 3598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback